Long-Term Artificial Sweetener Intake Tied to Obesity Risk
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 10, 2023 -- Long-term intakes of artificial sweetener (ArtSw), including aspartame, saccharin, or diet soda, may increase fat volume and risk for incident obesity, according to a study published online July 13 in the International Journal of Obesity.
Brian T. Steffen, Ph.D., from the University of Minnesota School of Medicine in Minneapolis, and colleagues assessed whether habitual, long-term ArtSw or diet beverage intakes are related to greater adipose tissue depot volumes and anthropometry-related outcomes. The analysis included 3,088 participants in the Coronary Artery Risk Development in Young Adults cohort, who were followed for 25 years.
The researchers found that total ArtSw, aspartame, saccharin, and diet beverage intakes were positively associated with volumes of visceral, intermuscular, and subcutaneous adipose tissue volumes. However, no associations were seen for sucralose intake. Total ArtSw, saccharin, aspartame, and diet beverage intakes also were associated with greater body mass index, body weight, and waist circumference, as well as increases during follow-up. ArtSw, including diet soda, was associated with a greater risk for incident obesity during a median 17.5-year follow-up, with the exception of saccharin.
"These findings underscore the importance of finding alternatives to artificial sweeteners in foods and beverages, especially since these added sweeteners may have negative health consequences," principal investigator Lyn Steffen, Ph.D., M.P.H., also from the University of Minnesota, said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Small Differences in Weight Change With First-Line Antidepressants
MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...
Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...
Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD
THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.